328 related articles for article (PubMed ID: 22336246)
1. JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
Kong D; Yamori T
Bioorg Med Chem; 2012 Mar; 20(6):1947-51. PubMed ID: 22336246
[TBL] [Abstract][Full Text] [Related]
2. The microculture-kinetic (MiCK) assay: the role of a drug-induced apoptosis assay in drug development and clinical care.
Bosserman L; Prendergast F; Herbst R; Fleisher M; Salom E; Strickland S; Raptis A; Hallquist A; Perree M; Rajurkar S; Karimi M; Rogers K; Davidson D; Willis C; Penalver M; Homesley H; Burrell M; Garrett A; Rutledge J; Chernick M; Presant CA
Cancer Res; 2012 Aug; 72(16):3901-5. PubMed ID: 22865459
[TBL] [Abstract][Full Text] [Related]
3. Anticancer SAR models for MCF-7 and MDA-MB-231 breast cell lines.
Qamar S; Carrasquer CA; Cunningham SL; Cunningham AR
Anticancer Res; 2011 Oct; 31(10):3247-52. PubMed ID: 21965732
[TBL] [Abstract][Full Text] [Related]
4. Morphobase, an encyclopedic cell morphology database, and its use for drug target identification.
Futamura Y; Kawatani M; Kazami S; Tanaka K; Muroi M; Shimizu T; Tomita K; Watanabe N; Osada H
Chem Biol; 2012 Dec; 19(12):1620-30. PubMed ID: 23261605
[TBL] [Abstract][Full Text] [Related]
5. 1,3,5-Triazines: A promising scaffold for anticancer drugs development.
Cascioferro S; Parrino B; Spanò V; Carbone A; Montalbano A; Barraja P; Diana P; Cirrincione G
Eur J Med Chem; 2017 Dec; 142():523-549. PubMed ID: 29046238
[TBL] [Abstract][Full Text] [Related]
6. The effect of anticancer drugs on seven cell lines monitored by FTIR spectroscopy.
Derenne A; Verdonck M; Goormaghtigh E
Analyst; 2012 Jul; 137(14):3255-64. PubMed ID: 22673795
[TBL] [Abstract][Full Text] [Related]
7. NCI-60 Cell Line Screening: A Radical Departure in its Time.
Chabner BA
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26755050
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel drugs for promising targets.
Martell RE; Brooks DG; Wang Y; Wilcoxen K
Clin Ther; 2013 Sep; 35(9):1271-81. PubMed ID: 24054704
[TBL] [Abstract][Full Text] [Related]
9. Chromenes: potential new chemotherapeutic agents for cancer.
Patil SA; Patil R; Pfeffer LM; Miller DD
Future Med Chem; 2013 Sep; 5(14):1647-60. PubMed ID: 24047270
[TBL] [Abstract][Full Text] [Related]
10. Pathophysiologically relevant in vitro tumor models for drug screening.
Das V; Bruzzese F; Konečný P; Iannelli F; Budillon A; Hajdúch M
Drug Discov Today; 2015 Jul; 20(7):848-55. PubMed ID: 25908576
[TBL] [Abstract][Full Text] [Related]
11. Diving for drugs: tunicate anticancer compounds.
Cooper EL; Yao D
Drug Discov Today; 2012 Jun; 17(11-12):636-48. PubMed ID: 22406646
[TBL] [Abstract][Full Text] [Related]
12. Improving the odds of success in antitumoral drug development using scoring approaches towards heterocyclic scaffolds.
Ion GND; Olaru OT; Nitulescu G; Olaru II; Tsatsakis A; Burykina TI; Spandidos DA; Nitulescu GM
Oncol Rep; 2020 Aug; 44(2):589-598. PubMed ID: 32627025
[TBL] [Abstract][Full Text] [Related]
13. Development of a high-content screening assay panel to accelerate mechanism of action studies for oncology research.
Towne DL; Nicholl EE; Comess KM; Galasinski SC; Hajduk PJ; Abraham VC
J Biomol Screen; 2012 Sep; 17(8):1005-17. PubMed ID: 22706350
[TBL] [Abstract][Full Text] [Related]
14. An overview on the recent developments of 1,2,4-triazine derivatives as anticancer compounds.
Cascioferro S; Parrino B; Spanò V; Carbone A; Montalbano A; Barraja P; Diana P; Cirrincione G
Eur J Med Chem; 2017 Dec; 142():328-375. PubMed ID: 28851503
[TBL] [Abstract][Full Text] [Related]
15. In Search of Outliers. Mining for Protein Kinase Inhibitors Based on Their Anti-Proliferative NCI-60 Cell Lines Profile.
Ion GND; Nitulescu GM
Molecules; 2020 Apr; 25(8):. PubMed ID: 32290461
[TBL] [Abstract][Full Text] [Related]
16. Novel piperazinediones as antitumor agents.
Wang CL; Lee O; Hsiao G; Lian JF; Cheng YW
Anticancer Res; 2014 Aug; 34(8):4013-9. PubMed ID: 25075024
[TBL] [Abstract][Full Text] [Related]
17. A simple and reliable approach for assessing anticancer activity in vitro.
López-Lázaro M
Curr Med Chem; 2015; 22(11):1324-34. PubMed ID: 25666807
[TBL] [Abstract][Full Text] [Related]
18. Establishing a high-throughput and automated cancer cell proliferation panel for oncology lead optimization.
Lei M; Ribeiro H; Kolodin G; Gill J; Wang YS; Maloney D; Fan Y; Li S; Myer L; Beluch M; Zhang L; Schweizer L
J Biomol Screen; 2013 Oct; 18(9):1043-53. PubMed ID: 23733846
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome P450 1A1-mediated anticancer drug discovery: in silico findings.
Nandekar PP; Sangamwar AT
Expert Opin Drug Discov; 2012 Sep; 7(9):771-89. PubMed ID: 22716293
[TBL] [Abstract][Full Text] [Related]
20. Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery.
Ruggeri BA; Camp F; Miknyoczki S
Biochem Pharmacol; 2014 Jan; 87(1):150-61. PubMed ID: 23817077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
